Endocrine Abstracts

Aims: Spain has been one of the worst affected countries by the COVID-19 pandemic. A very strict lockdown at home was imposed with a tough restriction of mobility. We aimed to evaluate the impact of this exceptional scenario on glucose profile of patients with type 1 diabetes (T1D) prone to hypoglycemia using sensor-augmented pump (SAP).

Methods: Patients with T1D prone to hypoglycemia using SAP (640G Medtronic Minimed) for at least 6 months under the funding of a National Health Service were included in an observational, retrospective study. Data were collected in two periods: pre-lockdown (PL), February 23rd–March 7th and within lockdown (WL), April 1st to 14th 2020. The primary outcome was the difference in the proportion of time in target glucose range of 70–180 mg/dl (TIR). Additional glucometric data and total daily insulin were also analysed.

Results: 59 patients were included: 33 women, age 46.17 ± 13.0 years and disease duration of 30.2 ± 12.0 years. TIR 70–180 mg/dl (67.6 ± 11.8 vs 69.8 ± 12.0%), time > 180 (28.1 ± 13.6 vs 25.5 ± 13.1%), time > 250 (6.9 ± 6.1 vs 5.1 ± 4.8) and Glucose Management Indicator (GMI) (6.94 ± 0.8 vs 6.75 ± 0.7%) significantly improved (PL vs WL, respectively, P < 0.05). Time in hypoglycemia, coefficient of variation, sensor usage and total daily insulin dose remained unchanged.

Conclusions: Lockdown conditions imposed by the COVID-19 pandemic may be managed successfully in terms of glycemic control by population with DT1 prone to hypoglycemia using SAP. The strict daily routine at home could probably explain the improvement in the time in glycemic target without increasing the time hypoglycemia.